Washington University registers Phase Ib trial pairing Sip-T with N-803 in resistant prostate cancer
A new dose-finding study will test Dendreon's Sipuleucel-T alongside ImmunityBio's N-803 in patients whose prostate cancer has resisted androgen pathway therapy.
This week brought one new trial registration relevant to the company.
- A Phase Ib study led by Washington University School of Medicine, with Dendreon and ImmunityBio as collaborators, is not yet recruiting. The trial will use a de-escalation design with a modified 3+3 approach to work out safety, tolerability, and a recommended Phase II dose for pairing standard of care Sip-T with N-803 in men with metastatic prostate cancer resistant to androgen pathway modulation.1 Enrollment is planned at 30 participants, with treatment lasting up to 8 weeks1 and estimated primary completion set for April 2029.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.